We are looking for a new Product Manager of Rare Disease – Congenital Hyperinsulinism (CHI) who has extensive Commercial experience leading across multiple functions with complementary expertise in marketing for rare diseases in the United States, Europe and other large markets.
If this sounds like you, and you are ready to take on a broad area of responsibilities with an independent attitude, then keep reading.
In collaboration with the commercial team, you will be accountable for creating and supporting implementation of the product strategy and launch plan including tactical branded materials including website content creation, promotional collateral development, congress planning and execution, product claims and positioning opportunities, vendor/agency management, HCP and patient market research, and promotional material review process. The initial focus is the support of the US launch, which may expand to more global content, such as Europe and ROW.
This is a very visible, hands-on role interfacing with multiple cross-functional teams and has significant opportunity to create long term impact throughout our organization with deep marketing capabilities and structured collaboration. The majority of the Product Manager’s time will be spent in the Copenhagen, DK office.
You will report to our Sr. Director, Head of Commercial Strategy, who reports directly to the VP of Commercial.
Responsibilities
- Maintain a comprehensive and up-to-date understanding of US HCP, Center of Excellence, and patient/caregiver landscape for CHI, with a view to support launch activities to ensure better patient support in this rare disease space
- Identify market research requirements and lead projects with external vendors
- Work with team members to maintain a comprehensive and up-to-date understanding of the competitive environment and continuously assess potential impact on current markets.
- Support the commercial team in the development of a global launch strategy and required pre-market development activities and market research
- Establish a brand plan and positioning opportunity with tactical elements in collaboration with cross-functional project teams within the organization.
- Represent the Commercial marketing function in project review committee meetings, cross-functional project teams, and field facing teams
- Development of promotional materials including training materials for field facing teams
- Presenting to and training of commercial field staff
- Review and analyze market/sales data objectively to highlight opportunities and risks
- In collaboration with the Sr. Director, maintain budget responsibilities and aid in preparation of yearly budget.
- Support Sr. Director in the creation of the LCM plan
Candidate profile
- Degree in life sciences or business; advanced degree preferred (e.g. MBA).
- Experience in the pharmaceutical or biotech industry with 5+ years of Commercial experience across multiple functions.
- Solid understanding of US marketing, including promotional regulatory environment
- Recognized leadership skills in direct and matrixed environments and the ability to align different parts of the organization to enable effective decision making.
- Demonstrated ability to metabolize high-level strategic thinking into detailed operational implementation. This position will be called on to pivot between various commercial workstreams depending on the current business environment.
- Demonstrated excellence in effective communication, influencing, and negotiation for a wide variety of audiences.
- Ability to build strong collaborative relationships with project team members and executives and demonstrate the ability to assimilate and apply new knowledge rapidly.
- Excellent oral and written English communication skills a must.
Bonding to innovate
Our employees are fundamental to our success, and we continue to be able to attract and retain people with vast experience and talent. We have a unique culture, characterized by excellent teamwork and strong engagement across the organization.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other.
We bond as a result of our entrepreneurial culture where our people are encouraged to pursue their ideas and turn them into reality. We are curious about each other’s knowledge and expertise.
We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Zealand Pharma is a place where everyone is heard and contributes to the success, we all want to experience.
The Zealand Pharma DNA builds on four values: (1) We are bold, (2) We empower people, (3) We work as one team, and
Let’s bond and be bold
We offer a combined compensation package which includes a base salary, pension, bonus, and a possibility to join our employee share program. We care about our employees’ well-being and offer health insurance, use of massage, fitness, and a range of social clubs and activities.
To find out more about working at Zealand, visit https://www.zealandpharma.com/careers/zealand-as-a-workplace/
Interested? Please apply no later than October 2, 2024 or as soon as possible. The applications will be reviewed as they come in.
For further information, please contact Camilla Westergaard Borgen at cborgen@zealandpharma.com.
About Congenital Hyperinsulinism
Congenital Hyperinsulinism (CHI) is the most frequent cause of severe and persistent hypoglycemia in newborns, infants, and children. CHI is caused by a defect in pancreatic beta-cells, resulting in the insulin overproduction and leading to frequent, recurrent and often severe episodes of low glucose (hypoglycemia).
Some forms of hyperinsulinism are transient and others arise from genetic defects and can persist through life. In both cases, frequent, recurrent and severe episodes of hypoglycemia in patients with CHI may result in brain damage. Complex care, including continuous enteral feeding or intravenous glucose, can result in lengthy and frequent hospitalizations that make daily life difficult. More than half of CHI patients may be sub-optimally treated with current therapies. For more information, please visit Congenitalhi.org.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
